A review of augmentation therapy for alpha-1 antitrypsin deficiency

Manish Mohanka, Danai Khemasuwan, James K. Stoller

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema. Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT). Augmentation therapy was first approved by the United States Food and Drug Administration (FDA) in 1987 for emphysema associated with severe AATD and today, six augmentation therapy preparations, all of which derive from pooled human plasma, have received FDA approval. Areas covered: This paper reviews augmentation therapy for AATD, including the various available commercial preparations, their processing and biochemical differences, evidence regarding biochemical and clinical efficacy, patterns of clinical use, adverse effect profiles, cost-effectiveness and potential uses in conditions other than emphysema associated with AATD. Novel and emerging strategies for treating AATD are briefly discussed next, including alternative dosing and administration strategies, recombinant preparations, small molecule inhibitors of neutrophil elastase and of AAT polymerization, autophagy-enhancing drugs and gene therapy approaches. Expert opinion: We conclude with a discussion of our approach to managing patients with AATD and use of augmentation therapy.

Original languageEnglish (US)
Pages (from-to)685-700
Number of pages16
JournalExpert Opinion on Biological Therapy
Volume12
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

alpha 1-Antitrypsin Deficiency
alpha 1-Antitrypsin
Emphysema
United States Food and Drug Administration
Plasma (human)
Therapeutics
Secretory Proteinase Inhibitory Proteins
Drug Approval
Autophagy
Expert Testimony
Drug therapy
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Gene therapy
Intravenous Infusions
Polymerization
Liver Cirrhosis
Genetic Therapy
Cost-Benefit Analysis
Cost effectiveness
Liver

Keywords

  • Alpha-1 antitrypsin
  • Augmentation therapy
  • Cirrhosis
  • Emphysema
  • Gene therapy
  • Panniculitis
  • Protease inhibitor
  • Pulmonary function test

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

A review of augmentation therapy for alpha-1 antitrypsin deficiency. / Mohanka, Manish; Khemasuwan, Danai; Stoller, James K.

In: Expert Opinion on Biological Therapy, Vol. 12, No. 6, 06.2012, p. 685-700.

Research output: Contribution to journalArticle

Mohanka, Manish ; Khemasuwan, Danai ; Stoller, James K. / A review of augmentation therapy for alpha-1 antitrypsin deficiency. In: Expert Opinion on Biological Therapy. 2012 ; Vol. 12, No. 6. pp. 685-700.
@article{03753f232f3e4a4b9113913e21b1cb71,
title = "A review of augmentation therapy for alpha-1 antitrypsin deficiency",
abstract = "Introduction: Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema. Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT). Augmentation therapy was first approved by the United States Food and Drug Administration (FDA) in 1987 for emphysema associated with severe AATD and today, six augmentation therapy preparations, all of which derive from pooled human plasma, have received FDA approval. Areas covered: This paper reviews augmentation therapy for AATD, including the various available commercial preparations, their processing and biochemical differences, evidence regarding biochemical and clinical efficacy, patterns of clinical use, adverse effect profiles, cost-effectiveness and potential uses in conditions other than emphysema associated with AATD. Novel and emerging strategies for treating AATD are briefly discussed next, including alternative dosing and administration strategies, recombinant preparations, small molecule inhibitors of neutrophil elastase and of AAT polymerization, autophagy-enhancing drugs and gene therapy approaches. Expert opinion: We conclude with a discussion of our approach to managing patients with AATD and use of augmentation therapy.",
keywords = "Alpha-1 antitrypsin, Augmentation therapy, Cirrhosis, Emphysema, Gene therapy, Panniculitis, Protease inhibitor, Pulmonary function test",
author = "Manish Mohanka and Danai Khemasuwan and Stoller, {James K.}",
year = "2012",
month = "6",
doi = "10.1517/14712598.2012.676638",
language = "English (US)",
volume = "12",
pages = "685--700",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - A review of augmentation therapy for alpha-1 antitrypsin deficiency

AU - Mohanka, Manish

AU - Khemasuwan, Danai

AU - Stoller, James K.

PY - 2012/6

Y1 - 2012/6

N2 - Introduction: Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema. Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT). Augmentation therapy was first approved by the United States Food and Drug Administration (FDA) in 1987 for emphysema associated with severe AATD and today, six augmentation therapy preparations, all of which derive from pooled human plasma, have received FDA approval. Areas covered: This paper reviews augmentation therapy for AATD, including the various available commercial preparations, their processing and biochemical differences, evidence regarding biochemical and clinical efficacy, patterns of clinical use, adverse effect profiles, cost-effectiveness and potential uses in conditions other than emphysema associated with AATD. Novel and emerging strategies for treating AATD are briefly discussed next, including alternative dosing and administration strategies, recombinant preparations, small molecule inhibitors of neutrophil elastase and of AAT polymerization, autophagy-enhancing drugs and gene therapy approaches. Expert opinion: We conclude with a discussion of our approach to managing patients with AATD and use of augmentation therapy.

AB - Introduction: Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema. Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT). Augmentation therapy was first approved by the United States Food and Drug Administration (FDA) in 1987 for emphysema associated with severe AATD and today, six augmentation therapy preparations, all of which derive from pooled human plasma, have received FDA approval. Areas covered: This paper reviews augmentation therapy for AATD, including the various available commercial preparations, their processing and biochemical differences, evidence regarding biochemical and clinical efficacy, patterns of clinical use, adverse effect profiles, cost-effectiveness and potential uses in conditions other than emphysema associated with AATD. Novel and emerging strategies for treating AATD are briefly discussed next, including alternative dosing and administration strategies, recombinant preparations, small molecule inhibitors of neutrophil elastase and of AAT polymerization, autophagy-enhancing drugs and gene therapy approaches. Expert opinion: We conclude with a discussion of our approach to managing patients with AATD and use of augmentation therapy.

KW - Alpha-1 antitrypsin

KW - Augmentation therapy

KW - Cirrhosis

KW - Emphysema

KW - Gene therapy

KW - Panniculitis

KW - Protease inhibitor

KW - Pulmonary function test

UR - http://www.scopus.com/inward/record.url?scp=84861319134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861319134&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.676638

DO - 10.1517/14712598.2012.676638

M3 - Article

C2 - 22500781

AN - SCOPUS:84861319134

VL - 12

SP - 685

EP - 700

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -